

re:Vive 2.0

The New Reality is More Than a Wearable Visual Field

Newly added testing modalities expand your practice's capabilities using a single piece of equipment and increase the opportunity to boost revenue with a free cloud-based upgrade.



Visual defects affect millions, with countless individuals going undiagnosed due to lack of access to screening. Heru continues to transform the future of eyecare through wearable technology by breaking down barriers and improving access to screening in a single multi-modal platform, saving you both time and space.

Age-related macular degeneration (AMD) is a silent thief, stealing sight without warning. In the coming decades, all things remaining constant, the number of people with AMD will double, impacting 22 million people in the U.S. alone¹. We have expanded the capabilities of re:Vive™ by Heru™ with our latest software update.

re:Vive 2.0 now includes the new dark adaptometer increasing your marketability and providing you more avenues for reimbursement to help build a high-yield practice. Plus much more:

re:Vive 2.0 features:

- Color Vision – CPT 92283
- Contrast Sensitivity
- Dark Adaptation – CPT 92284



Screening for disease with re:Vive is straight forward and completed as part of your comprehensive eye exam.

The new testing modalities in **re:Vive 2.0** are seamlessly delivered to the platform over-the-air without disrupting your clinic and are co-billable with visual field, OCT, and office visits.

Color Vision



Optimize efficiency and the patient experience.

Color vision testing is a well-accepted tool in the detection of inherited or acquired eye diseases. Screening color vision testing (Ishihara) is covered as part of an eye exam. Extended color vision testing may be ordered when a patient fails the screening color vision test or has a sign, symptom or history that warrants additional testing.

re:Vive now features the Ishihara color vision test, and the Farnsworth D-15 extended color vision test, providing your practice with a fast, efficient solution for detecting and classifying color vision deficiencies. The D-15 extended color vision test (CPT 92283) has an average national reimbursement of \$56.16² with many supported ICD-10 codes.

Contrast Sensitivity



Document and monitor macular health.

Contrast sensitivity is an essential measure of visual function. Studies show that low contrast sensitivity can also be a symptom of other eye conditions, such as glaucoma and age-related macular degeneration (AMD). The re:Vive 2.0 Contrast Sensitivity exam is simple, fast, and provides your patients with tangible proof of the subtle, often slow-changing effects of diminishing vision.

This new feature moves Contrast Sensitivity testing out of the exam lane,

giving you more time to interpret data and consult with your patients. Perform the exam in natural room lighting without a clinician or technician as the Heru "personality" instructs and monitors your patients, allowing you to tend to your growing practice.

Developed in partnership with MacuHealth, re:Vive leverages the science that connects Contrast Sensitivity with the early stages of AMD, to provide an efficient way to document and monitor the functional macular health.

Dark Adaptation



Stay on the cutting edge of early AMD diagnosis and treatment.

Early AMD diagnosis leads to better patient outcomes. With re:Vive's new Dark Adaptation (CPT 92284) modality, you evaluate the retinal function by measuring a patient's dark adaptation. Impaired dark adaptation has been associated with early signs and symptoms of AMD. Early diagnosis of AMD enables better management of the patient, to reduce the risk of vision loss, improve patient outcomes and increase revenue for your practice.

Developed in partnership with the Bascom Palmer Eye Institute, the re:Vive Dark Adaptation exam measures

the Adaptation Index value. Our proprietary technology enables Dark Adaptation measurements using a dimmer flash brightness compared to other devices, increasing patient comfort and compliance.

Why spend \$49k on a single diagnostic measurement? re:Vive is affordable and allows for an objective measurement of retinal function at a fraction of the cost of traditional testing using a single wearable platform. Boost your practice revenue using the existing CPT code with a high average national reimbursement of \$60.02³.

Elevating the standard of care in vision diagnostics through continuous innovation.

Heru established the new standard of care with re:Vive by Heru, which combines wearable technology and augmented reality. re:Vive 2.0 enables you to treat more patients with a multi-modal cloud-based platform utilizing existing CPT codes, providing your practice with increased avenues for reimbursement to achieve your revenue targets. We're committed to providing you with the resources you need through over the air updates so you can focus on patient care.

Visit seeheru.com to schedule a demo, or call 844-SEE-HERU.

1. National Institutes of Health, National Eye Institute. Prevalence of Blindness** Data--Data Tables, Summary of Eye Disease Prevalence Data: "Prevalence of Cataract, Age-Related Macular Degeneration, and Open-Angle Glaucoma Among Adults 40 Years and Older in the United States" https://nei.nih.gov/eyedata/pbd_tables Archives of Ophthalmology, Volume 122, April 2004.

2. Corcoran Consulting Group. 2018

3. Center for Medicare & Medicaid Services (CMS). <https://www.cms.gov/medicare/physician-fee-schedule/search?Y=0&T=0&HT=0&CT=0&HI=92284&M=5>. July 2021.

